SITE004-0229

SITE004 (DEU) › SITE004-0229

SITE004-0229

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2026-05-29

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-07 (study day 93); relationship: NOT RELATED

moderate assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-29 (study day 56); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 52); relationship: RELATED

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-06 (study day 33); relationship: NOT RELATED

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-06 (study day 33); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.